Thoracopulmonary Department, University of Milan, Fondazione IRCCS Cá Granda Ospedale Maggiore Policlinico, Via Francesco Sforza n. 28, 20122 Milan, Italy.
Respir Med. 2012 Feb;106(2):205-14. doi: 10.1016/j.rmed.2011.10.001. Epub 2011 Oct 28.
To estimate the prevalence of partly controlled and uncontrolled asthmatic patients, to evaluate quality of life and healthcare resource consumption.
Cross-sectional phase followed by a 12-month prospective phase. Asthma Control Test and the EQ-5D were used.
2853 adult patients recruited in 56 Hospital Respiratory Units in Italy were evaluated: 64.4% had controlled asthma, 15.8% partly controlled asthma and 19.8% were uncontrolled. The mean (SD) EQ-5D score was 0.86 (0.17) in controlled, 0.75 (0.20) in partly controlled and 0.69 (0.23) in uncontrolled patients (p<0.001 between groups). The number of patients requiring hospitalization or emergency room visits was lower in controlled (1.8% and 1.6%, respectively) than in partly controlled (5.1% and 11.5%) and uncontrolled (6.4% and 18.6%). A combination of an inhaled corticosteroid and a long-acting beta-2 agonist was the reported therapy by 56.0% of patients, with the rate of controlled asthma and improved quality of life being higher in patients on extrafine beclomethasone/formoterol compared to budesonide/formoterol (p<0.05) and fluticasone/salmeterol (p<0.05 for quality of life).
Asthma control is achieved in a good proportion of Italian patients. Differences may be detected in a real-life setting in favor of extrafine beclomethasone/formoterol combination.
评估部分控制和未控制哮喘患者的患病率，评估生活质量和医疗资源的消耗。
横断面阶段后进行 12 个月的前瞻性阶段。使用哮喘控制测试和 EQ-5D。
在意大利的 56 个医院呼吸科共招募了 2853 名成年患者：64.4%的患者哮喘得到控制，15.8%的患者哮喘部分得到控制，19.8%的患者哮喘未得到控制。控制组患者的平均（SD）EQ-5D 评分为 0.86（0.17），部分控制组为 0.75（0.20），未控制组为 0.69（0.23）（组间差异<0.001）。控制组住院或急诊就诊的患者比例较低（分别为 1.8%和 1.6%），而部分控制组为 5.1%和 11.5%，未控制组为 6.4%和 18.6%。56.0%的患者报告使用吸入皮质激素和长效β2 激动剂联合治疗，与布地奈德/福莫特罗和氟替卡松/沙美特罗相比（生活质量方面，p<0.05），使用丙酸倍氯米松/福莫特罗的患者哮喘得到控制的比例更高，生活质量也有所改善。
在意大利的患者中，哮喘控制达到了较好的比例。在现实环境中可能会发现差异，有利于使用丙酸倍氯米松/福莫特罗联合治疗。
